Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 32, Issue 12, Pages 1113-1117Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2018.09.005
Keywords
Bardoxolone methyl; Chronic kidney disease; Obesity; Metabolic effects; HbA(1c); Randomized clinical trial
Categories
Funding
- Reata Pharmaceuticals
Ask authors/readers for more resources
Aims: Obesity is associated with progression of chronic kidney disease (CIO). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl. Methods: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30 ml./min/1.73 m(2)) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo. Results: BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -53 kg; p < 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control. Conclusions: Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI. (C)2018 The Authors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available